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High-level arsenic exposure is consistently associated with QT prolongation, a risk factor for arrhythmia and
sudden cardiac death. Arsenic may act on QT by increasing cardiac calcium currents. The authors hypothesized
that low-level arsenic exposure would be associated with QT duration and that this effect would be stronger among
persons not using calcium channel blockers. They performed a cross-sectional analysis in elderly men from the
Normative Aging Study to analyze associations between toenail arsenic and QT and heart rate-corrected QT (QTc)
durations and to examine effect modification by calcium channel blocker use, using linear regression and adjusting
for potential confounders. Participants were examined in Boston, Massachusetts, between 2000 and 2002 or in
2006. An interquartile range increase in arsenic concentration was associated with a 3.8-millisecond increase in
QT (95% confidence interval: 0.82, 6.8) and a 2.5-millisecond increase in QTc (95% confidence interval: 0.11, 4.9).
There was no evidence of effect modification by medication use for either QT (P ¼ 0.93) or QTc (P ¼ 0.58). The
authors observed positive associations between a biomarker of arsenic exposure and QT duration but found no
evidence of effect modification by calcium channel blocker use, possibly because of modest power.
antioxidants; arrhythmias, cardiac; arsenic; calcium channel blockers; cardiovascular diseases; environmental
health; long QT syndrome
Abbreviations: hERG, human ether-a go-go related gene product protein; QTc, heart rate-corrected QT.
Prolongation of the QT interval is a risk factor for arrhyth-
mia and sudden cardiac death (1, 2). The QT interval is
measured as the time elapsed between the beginning of
the QRS complex and the end of the T wave in an electro-
cardiogram. It corresponds to the length of a ventricular
electrical systole, covers the sustained calcium influx period
of the heart cycle, and represents the duration of depolar-
ization and repolarization. Because the duration of this in-
terval is dependent on heart rate, it is usually adjusted for
heart rate and expressed in a corrected form (QTc) in order
to aid interpretation. Normal values for QT duration range
between 300 and 440 milliseconds.
Arsenic prolongs the QT interval in animal studies and in
cases of acute arsenic poisoning in humans (3–7). In addition,
clinical studies demonstrate consistently that arsenic triox-
ide, used to treat acute promyelocytic leukemia, induces QT
prolongation, torsades de pointes, and sudden death (8–10).
Finally, 3 population-based epidemiologic studies found
a positive association between high-level environmental
arsenic exposure and QT interval duration (11–13). No stud-
ies have examined the relation between QT interval length
and low-level arsenic exposure or have looked at the associ-
ation between any level of arsenic exposure and QT by using
a biomarker of dose. Instead, surrogates such as water
concentration have been used.
We hypothesized that low-level environmental arsenic
exposure would prolong QT interval duration in a general
population study. We conducted a cross-sectional examina-
tion of the association between toenail arsenic concentration
and QT and QTc interval lengths. Because arsenic exposure
may prolong the QT interval by increasing cardiac calcium
currents, which regulate the plateau phase of the cardiac
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action potential (3), we assessed for effect modification by
current calcium channel blocker use. Further, because oxi-
dative stress may mediate the association between arsenic




Our participants were from the Veterans Administration
Normative Aging Study. This is an ongoing longitudinal
study of aging established in 1963, details of which have
been published previously (16). Briefly, the Normative
Aging Study is a closed cohort of 2,280 male volunteers
from the Greater Boston area aged 21–80 years at entry,
who enrolled after an initial health screening determined
that they were free of known chronic medical conditions.
Participants were reevaluated every 3–5 years by using
detailed on-site physical examinations and questionnaires.
All active participants were contacted prior to their study
visit and asked to bring toenails when they presented for the
visit between November 2000 and November 2002 (n ¼
512) or between July 2006 and December 2006 (n ¼ 64).
Nonparticipants failed to do so (n ¼ 240), did not have
acceptable QT measurements because of irregular electro-
cardiograms (n ¼ 181), were missing information regarding
C-reactive protein concentrations (n¼ 7), and/or had toenail
arsenic concentrations below the detection limit (n ¼ 2).
Our analyses included 226 participants with information
on all study variables who contributed toenail samples be-
tween November 2000 and November 2002 (n ¼ 204) or
between July 2006 and December 2006 (n ¼ 22).
Physical parameters and medical history
Study center visits followed an overnight fast and absten-
tion from smoking. Physical examinations included mea-
surement of height and weight, and body mass index was
calculated (weight (kg)/height (m)2). A physician measured
blood pressure using a standard mercury sphygmomanom-
eter with a 14-cm cuff while the participant was seated.
Questionnaires evaluated smoking habits and medication
use, with responses confirmed by an on-site physician.
C-reactive protein concentrations were determined by using
a high-sensitivity immunoturbidimetric assay on the Hitachi
917 analyzer (Roche Diagnostics, Indianapolis, Indiana)
(17). Fasting serum glucose concentrations were measured
by using the hexokinase method, with measurements per-
formed in duplicate on an autoanalyzer (18).
Antioxidant and fish intakes were determined by using
a food frequency questionnaire (19, 20). We calculated daily
intakes of antioxidant nutrients by multiplying the fre-
quency of consumption of each unit by the nutrient content
of the specified portion and adding amounts from dietary
supplements. Fish questions included canned tuna, shellfish,
dark-meat fish, and other fish.
Toenail sample collection and arsenic analysis
Toenail samples from all 10 toes were collected. The
whole sample was precleaned before analysis to remove
extraneous contaminants by using the following procedure.
Toenail samples were sonicated for 15 minutes in approxi-
mately 10 mL of 1% Triton X-100 solution (Dow Chemical
Company, Midland, Michigan) in 15-mL plastic tubes. After
sonication, samples were rinsed several times with distilled
deionized water and dried at 60C for 24 hours in a drying
oven.
Toenail samples were weighed into a 15-mL plastic tube,
digested with 1 mL of concentrated nitric acid for 24 hours,
and then diluted to 5 mL with deionized water. Samples
were further diluted as needed. Acid-digested samples were
analyzed by an inductively coupled plasma mass spectrom-
eter (Elan 6100; PerkinElmer, Inc., Waltham, Massachu-
setts). Analysis was performed by using an external
calibration method with tellurium as the internal standard
for arsenic.
Quality control measures included analysis of the initial
calibration verification standard (standard reference mate-
rial 1643e (trace elements in water); National Institute of
Standards and Technology, Gaithersburg, Maryland),
a 1-ng/mL standard arsenic solution, continuous calibration
standards, and a procedural blank. Certified reference ma-
terial GBW 07601 (human hair; Shanghai Institute of
Nuclear Research, Chinese Academy of Sciences, Shanghai,
China) was used as the quality control sample. We used
a large preparation of GBW 07601 (2 g/L) to monitor daily
variation.
The between-assay coefficient of variation for arsenic
was 0.1. The detection limit for the analytical solution
was 0.2 ng/mL. The detection limit for the sample itself
varied according to sample weight and was equal to the
detection limit for the analytical solution multiplied by the
dilution factor. Because the weight of the sample varied
from 0.002 g to 0.9 g, the detection limit varied from
0.001 lg/g to 0.42 lg/g. The average detection limit for this
analysis was 0.02 lg/g. Two individuals had toenail arsenic
concentrations below the detection limit and were excluded
from the present study. Results were given as the average of
5 replicate measurements. Recovery of the analysis of the
quality control standard by this procedure is 90%–110%
with approximately 95% precision.
Electrocardiogram measurement and analysis
The electrocardiogram was measured with a 2-channel,
5-lead electrocardiogram monitor (Trillium 3000; Forest
Medical, East Syracuse, New York) over approximately
5–10 minutes, by using a sampling rate of 256 Hz per chan-
nel. This procedure is described in detail elsewhere (21, 22).
The electrocardiogram digital recordings were processed by
using personal computer-based software (Trillium Platinum
Holter Analysis Software for MSWindows; Forest Medical)
to create a Mathcad (Parametric Technology Corporation,
Needham, Massachusetts) file containing QT interval mea-
surements. AWin32 console application (Microsoft Corpo-
ration, Redmond, Washington) was used to obtain QT and
QTc values from the data. This application measured the QT
interval from the beat onset to the end of the Twave only on
normal or supraventricular beats and calculated the QTc
value in milliseconds using Bazett’s formula as described
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by Bednar et al. (23). The QT interval was not calculated if
the T wave did not have sufficient amplitude, as determined
by the program algorithm.
Statistical methods
We conducted a cross-sectional examination of the asso-
ciation between toenail arsenic concentration and QT dura-
tion measured at the same visit as toenail collection using
multivariate linear regression. We used a 2-sided P value of
P < 0.05 as the level of statistical significance for both the
main effect of arsenic and interaction terms.
The following covariates were selected as potential con-
founders on the basis of a thorough review of the relevant
literature: age, body mass index, mean arterial pressure,
fasting glucose, serum C-reactive protein, current cigarette
smoking (smoker vs. nonsmoker), and pack-years of smok-
ing. We chose to adjust for season and year of clinical visit
a priori. All covariates were included in regression models
regardless of statistical significance.
To test the dose-response relation of QT and QTc dura-
tions with toenail arsenic, we reexamined our model in R
using a penalized spline for arsenic. The penalized spline fits
a 12-df regression spline to the dose-response curve but
penalizes the coefficients of the spline, effectively constrain-
ing the number of degrees of freedom used. The degree of
penalty (and constraint) was chosen by using generalized
cross-validation (The R-Project for Statistical Computing;
available at http://www.r-project.org/).
We examined effect modification by calcium channel
blocker use and by antioxidant intake using interaction
terms and stratified analyses. To assess for modification by
antioxidant intake, we constructed a score representing the
combined intake of vitamin C, vitamin A, and total caro-
tene. For each nutrient, we assigned to participants a score
of 1–3, corresponding to their tertile of intake. The overall
intake score was obtained by summing scores for individual
dietary components and was partitioned into 3 categories:
low (scores 3–4), intermediate (scores 5–7), or high (scores
8–9). This analysis was performed on a subset of partici-
pants (n¼ 198), because data on antioxidants were available
only through 2005. Models examining effect modification
by antioxidant nutrients were adjusted for total daily energy
intake, as well as previously mentioned covariates.
We compared participants included in our analyses with
nonparticipants presenting during the period of toenail col-
lection using Student’s t test and chi-square analysis
and examined bivariate associations between arsenic and
participants’ characteristics using Student’s t test and the
Spearman correlation. The use of log-transformed arsenic
measures in our regression models did not significantly alter
the results (data not shown). We therefore used untrans-
formed metal measures in all analyses. We examined the
correlation between QTc and heart rate using Spearman’s r.
RESULTS
Our study population was composed of males with a mean
age of 73 years and a mean body mass index of 28 kg/m2
(Table 1). The mean QT and QTc interval durations for this
sample were 378 (standard deviation, 39) milliseconds and
395 (standard deviation, 30) milliseconds, respectively.
Both QT and QTc interval durations were approximately
normally distributed (data not shown). The median concen-
tration of toenail arsenic was 0.069 lg/g (interquartile
range, 0.052–0.11 lg/g). Participants and nonparticipants
differed with respect to season and year of clinical visit
(Table 1). Toenail arsenic concentrations were lower in the
winter (P ¼ 0.005) than during other seasons but were not
associated with any other covariates or with dark-meat fish
intake, other fish intake, shellfish intake, or intake of canned
tuna (P > 0.05). We reported median toenail arsenic con-
centrations by characteristics of participants in Table 2. QTc
interval duration was weakly correlated with heart rate (r ¼
0.13; P ¼ 0.05) (Figure 1).
We estimated the change in QT and QTc durations asso-
ciated with toenail arsenic concentration (Table 3) and ex-
pressed the results as the change associated with an
interquartile range (0.059 lg/g) increment in exposure to
arsenic. We found that a 0.059-lg/g increase in toenail ar-
senic was associated with a 3.8-millisecond increase in the
QT interval (95% confidence interval: 0.82, 6.8; P ¼ 0.01)
and a 2.5-millisecond increase in the QTc interval (95%
confidence interval: 0.11, 4.9; P ¼ 0.04).
We tested the dose-response relation for arsenic and QT
duration using penalized splines. For QT, generalized cross-
validation found that a linear curve was the best fit, while for
QTc a 1.26-df curve fit best. Hence, the dose-response curve
appeared to be essentially linear for both of these
associations.
We also examined effect modification by calcium channel
blocker use because of information from prior research find-
ings (3). Thirty-five participants reported using calcium
channel blockers at the time of data collection. Use of these
medications was not independently associated with QT or
QTc duration. We found no evidence of statistical interac-
tion between toenail arsenic and current calcium channel
blocker use for either QT (P ¼ 0.93) or QTc (P ¼ 0.58)
(data not shown).
Finally, we examined effect modification by antioxidant
intake in a subset of participants (Table 4). Intake of anti-
oxidant nutrients was not associated with either QT or QTc
duration. We found no evidence of statistical interaction
between toenail arsenic and antioxidant score for either
QT (P ¼ 0.28) or QTc (P ¼ 0.95). However, among persons
with low antioxidant intake, an interquartile range incre-
ment in arsenic exposure was associated with an 11-milli-
second increase in QT duration (95% confidence interval:
0.078, 22; P ¼ 0.05). Associations between arsenic and QT
duration were much smaller and not significant among par-
ticipants with intermediate or high antioxidant intake. We
did not observe a similar pattern in stratified analyses for
QTc duration.
DISCUSSION
Toenail arsenic concentration is positively associated
with QT and QTc interval durations in this cohort of elderly
men. We found no evidence of statistical interaction
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between toenail arsenic concentration and calcium channel
blocker use, possibly because of modest power to evaluate
effect modification. This is the first study to examine the
association between low-level environmental arsenic expo-
sure and QT duration or to evaluate the association between
any level of arsenic exposure and QT using an internal bio-
marker of dose. Our findings of even a modest relation
between toenail arsenic and QT interval length, if con-
firmed, may have important implications because of wide-
spread exposure to low or moderate levels of this metal
across the US population.
This study utilized an automated method to measure QT
duration. Automated methods have greater potential to per-
form objectively than manual measurements, and a recent
study testing the reproducibility of automated multichannel
QT interval measurements found that the use of an auto-
matic algorithm for QT analyses allowed for accurate and
highly repeatable QT measurements (24).
Because arsenic has a high affinity for sulfhydryl groups,
it accumulates in keratin-rich tissues such as toenails and
hair. These tissues provide an integrated measure of arsenic
dose from all routes of exposure. Toenails grow more slowly
than hair and are more protected from external environmen-
tal contaminants. Further, they provide a well-validated
measure of exposure to the metal from water, food, soil,
dust, and air (25). Because toenails are estimated to reflect
arsenic exposures from the preceding 12–18 months in the
general population, they represent much longer-term arsenic
exposures than blood or urine measurements (25, 26). Nails
usually grow more slowly in the elderly than in younger
individuals (25).
Toenail arsenic concentrations in our analysis were sim-
ilar to those of other US-based study populations (27, 28).
Previous studies have assessed primarily the effects of in-
organic arsenic, which is more toxic than the organic form.
The assay used to measure toenail arsenic concentration
does not distinguish between organic and inorganic forms
of arsenic. However, organic arsenic compounds are derived
mainly from seafood consumption (25), and the toenail ar-
senic concentration was not associated with fish or shellfish
intake in our study population.
Most of our participants were supplied with water, an
important source of inorganic arsenic, by the Massachusetts
Water Resources Authority (Boston, Massachusetts). Arsenic
is consistently undetectable (<1.0 lg/L) in this water sup-
ply, and other sources are likely in our study population
(23). Sources of inorganic arsenic exposure in the general
population include air, soil, dust, and food, particularly veg-
etables and rice (25, 29). Occupational sources of inorganic
arsenic exposure include mining, smelting operations, wood
preservation, and electronics (29).
Three cross-sectional, population-based analyses have as-
sessed the relation between high-level environmental arse-
nic exposure and QT duration. Studies conducted in Inner






(n 5 350) P Value
(2 sided)a
Mean (SD) No. % Mean (SD) No. %
Age, years 73 (6) 73 (7) 0.38
Body mass index, kg/m2 28 (4) 28 (4) 0.11
Smoking status
Smoker 10 4 16 5 0.92
Nonsmoker 216 96 332 95
Pack-years of smoking 33 (27) 31 (26) 0.52
Serum C-reactive protein, mg/L 4 (7) 3 (10) 0.60
Fasting glucose, mg/dL 107 (28) 106 (26) 0.58
Mean arterial pressure, mm Hg 94 (10) 94 (11) 0.78
Season of visit
Spring 63 28 74 21 0.01
Summer 49 22 99 28
Fall 63 28 123 35
Winter 51 23 54 15
Year of visit <0.001
2000 17 8 21 6
2001 135 60 141 40
2002 52 23 146 42
2006 22 10 42 12
Abbreviation: SD, standard deviation.
a Using Student’s t test and chi-square analysis, we compared participants included in our
analyses with nonparticipants presenting during the period of toenail collection.
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Table 2. Toenail Arsenic Concentrations by Characteristics of Participants (n ¼ 226),









<73 106 0.08 0.06
73 120 0.06 0.05
Body mass index, kg/m2
<25 54 0.07 0.07
25–29 123 0.07 0.06
30 49 0.08 0.04
Current smoking status
Smoker 10 0.09 0.12
Nonsmoker 216 0.07 0.06
Lifetime smoking, pack-years
<26 77 0.07 0.05
26 80 0.07 0.06
Serum C-reactive protein, mg/L
<1.8 113 0.07 0.06
1.8 113 0.07 0.05
Fasting glucose, mg/dL
<100 109 0.07 0.05
100 117 0.07 0.06
Mean arterial pressure, mm Hg
<95 112 0.08 0.06
95 114 0.07 0.06
Dark-meat fish intake, servings
<1/month 93 0.07 0.06
1/month–6/week 105 0.07 0.05
Other fish intake, servings
<1/month 60 0.07 0.06
1/month–6/week 138 0.07 0.05
Shellfish intake, servings
<1/month 84 0.06 0.06
1/month–6/week 114 0.07 0.05
Intake of canned tuna, servings
<1/month 56 0.07 0.05
1/month–6/week 142 0.07 0.05
Season of clinical visit
Spring 63 0.06 0.04
Summer 49 0.09 0.07
Fall 63 0.08 0.08
Winter 51 0.06 0.03
Year of clinical visit
2000 17 0.06 0.03
2001 135 0.07 0.06
2002 52 0.07 0.06
2006 22 0.09 0.07
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Mongolia and Bangladesh found positive associations be-
tween well water arsenic exposure and prevalence of abnor-
mal QTc prolongation (11, 13). A study conducted in
Turkey found positive associations between water arsenic
exposure and both QT and QTc interval lengths (12).
In the study conducted in Bangladesh, the mean well
water arsenic concentrations for the reference group and 2
exposed subgroups were<10 lg/L, 443 lg/L, and 493 lg/L,
respectively (13). In the study conducted in Turkey, the
mean water arsenic concentrations were 659 lg/L in the
exposed subgroup and 0 lg/L in the unexposed subgroup
(12). Finally, in the study by Mumford et al. (11) conducted
in Inner Mongolia, the exposure categories were <21, 100–
300, and 430–689 lg/L. The water arsenic concentrations
assessed in the 3 studies were much greater than both the
current (10 lg/L) and previous (50 lg/L) maximum con-
taminant level in the United States. These studies do not
allow direct insight into the arrhythmogenic effects of the
low level of arsenic exposure relevant to most US-based
study populations.
The study conducted in Inner Mongolia measured the
toenail arsenic concentration among study participants
(11). The low, medium, and high water exposure subgroups
had mean toenail arsenic concentrations of 1.21 lg/g, 9.79
lg/g, and 24.61 lg/g, respectively, with an overall mean of
11.8 lg/g. In contrast, the mean toenail arsenic concentra-
tion in our study was 0.10 lg/g (range, 0.02–0.86 lg/g). Our
findings of a positive association between toenail arsenic
concentration and QT duration are consistent with those
from the existing literature but extend it to much lower
exposure levels and the use of an internal biomarker of dose.
Arsenic may prolong QT interval duration by increasing
cardiac calcium currents, which regulate the plateau phase
of the cardiac action potential. The metal may also act by
reducing surface expression of the cardiac potassium chan-
nel human ether-a go-go related gene product protein
(hERG), which is essential for repolarization of cardiac
myocytes (3). Arsenic interferes with hERG trafficking to
the cell surface by inhibiting hERG-chaperone complexes.
The mechanism by which arsenic increases cardiac calcium
currents is unclear but may be the result of direct enzymatic
modification of the calcium channel or its accessory proteins
(3, 4). In addition to changes in cardiac ion channels, pos-
sible mechanisms of arsenic-induced QT prolongation in-
clude alterations in DNA repair and methylation, generation
of reactive oxygen species, and induction of cardiomyocyte
apoptosis (14, 15, 30).
The finding that arsenic may lengthen QT interval dura-
tion by increasing cardiac calcium currents prompted Ficker
et al. (3) to suggest that administration of calcium channel
blockers could ameliorate arsenic trioxide-induced QT pro-
longation during treatment of acute promyelocytic leuke-
mia. We therefore examined effect modification by current
calcium channel blocker use in our analysis. Our results
show no evidence of statistical interaction between toenail
arsenic and medication use. This study did not have suffi-
cient power to assess lower levels of effect modification
because of modest sample size, however, and tests for sta-
tistical interaction are hampered by low power in general.
Because reactive oxygen species may mediate the asso-
ciation between arsenic and QT duration (14, 15), we also
examined effect modification by antioxidant nutrients using
an intake score. Vitamin C, vitamin A, and total carotene are
all powerful antioxidants that may play a role in prevention
of cardiovascular disease (31, 32), and dietary antioxidants
may be interactive in their effects on cardiovascular health
(33). Few studies have computed antioxidant intake scores
from dietary data, and the validity of our score needs to be
evaluated in future analyses.
We did not find evidence of statistical interaction between
toenail arsenic and antioxidant intake for either QT or QTc
duration. We observed a strong association between arsenic
and uncorrected QT duration in the low antioxidant intake
group and not in the intermediate or high intake groups,
Figure 1. Correlation between QTc (heart rate-corrected QT) inter-
val duration and heart rate among Normative Aging Study participants
(n ¼ 226), Boston, Massachusetts, 2000–2002, 2006. The QTc in-
terval duration is weakly correlated with heart rate (Spearman’s
r ¼ 0.13; 2-sided P ¼ 0.05). ms, milliseconds.
Table 3. Estimated Change in QT and QTc Interval Durations
Associated With an Interquartile Rangea Increase in Toenail Arsenic
Concentration Among Normative Aging Study Participants





QT interval 3.8* 0.82, 6.8
QTc interval 2.5* 0.11, 4.9
Abbreviations: ms, millisecond(s); QTc, heart rate-corrected QT.
* P < 0.05 (2 sided).
a Corresponding to a 0.059-lg/g increment of toenail arsenic con-
centration.
b All multivariate linear regression models are adjusted for
age, cigarette smoking (smoker vs. nonsmoker), pack-years of
smoking, season of clinical visit, body mass index, serum C-reactive
protein, serum fasting glucose, year of clinical visit, and mean arterial
pressure.
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which, given our limited power, supports further research
examining this interaction. However, we did not find a sim-
ilar pattern in stratified analyses for QTc, which is the more
clinically relevant measure of QT duration.
The changes we are examining do not rise to the level of
clinical QT prolongation requiring a medical response, and
the relation between QT duration and sudden cardiac death
is clear only at the extremes of QT interval length (34).
However, variations in blood pressure and cholesterol levels
within the normal range have been associated with cardiac
events and deaths (35, 36). Hence, controllable disturbances
that shift the distribution of cardiac risk factors are of public
health—as opposed to individual or clinical—concern.
Moreover, part of our goal is to identify mechanisms by
which environmental exposures may be related to cardio-
vascular disease, and these results indicate that disturbance
of normal cardiac repolarization may be part of that path-
way. Hence, we believe the findings are of interest regard-
less of the direct public health consequences of the changes.
This is particularly true given the very low arsenic levels
found in this population. Higher doses are found in areas
with arsenic in groundwater and may result in greater
impacts.
One potential limitation of our study is its cross-sectional
design, which restricts inferences about causality. In addi-
tion, our sample size, though comparable to previous anal-
yses, is relatively modest and does not provide satisfactory
power to examine effect modification. Further, suitable in-
formation on additional important antioxidants such as
vitamin E was not available for our analysis. Our study
population was homogenous, consisting entirely of elderly
men, 98% of whom were white. However, our findings are
consistent with research conducted in more diverse popula-
tions. The finding of associations at these exposure levels, if
confirmed, suggests that current efforts to limit arsenic ex-
posure in the general population may be inadequate.
More research using a prospective cohort design is needed
to assess the relation between low-level arsenic exposure and
QT duration among large, diverse study populations. Future
studies should also evaluate the association between low-
level environmental arsenic exposure and QT interval dura-
tion among women because of their increased susceptibility
to arsenic’s effects on QT prolongation (11). Potential effect
modification by calcium channel blocker use and antioxidant
intake should be investigated in high-powered analyses.
Our findings show a positive association between toenail
arsenic concentration and QT and QTc interval durations. We
found no evidence of effect modification by calcium channel
blocker use, possibly because of modest power. These results
provide new information to guide future research regarding the
arrhythmogenic effects of environmental arsenic exposure.
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